• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OncoSec wins fast track designation for electroporation combo therapy

February 27, 2017 By Sarah Faulkner

OncoSec MedicalOncoSec wins fast track designation for electroporation combo therapy (NSDQ:ONCS) said today that it won Fast Track Designation from the FDA for its ImmunoPulse IL-12 electroporation gene therapy for the treatment of metastatic melanoma.

The biotech company’s electroporation device is designed to locally deliver DNA-based interleukin-12 to stimulate the immune system and fight off cancer cells. The ImmunoPulse device delivers a sequence of short-duration electrical pulses to increase the cancer cell membrane’s permeability and more efficiently deliver the IL-12 gene therapy.

The federal watchdog granted OncoSec Fast Track designation for patients with metastic melanoma that have not responded to treatment with pembrolizumab or nivolumab.

“With the number of melanoma patients now being treated with either pembrolizumab or nivolumab in either the 1st-  or 2nd-line settings, there will be an increasing number of patients who will not respond to therapy. Thus, there is a clear need for treatments that can rescue these patients and help them benefit from these immunotherapies,” president & CEO Punit Dhillon said in prepared remarks. “With the recent presentation of our interim data from our ongoing combination study with pembrolizumab in patients predicted not to respond to single-agent anti-PD-1 therapy, we are increasingly confident in ImmunoPulse IL-12 to potentially convert ‘cold’ tumors to ‘hot’ tumors to effectively and safely improve the response rates of these patients.”

“This Fast Track designation by the FDA serves as an additional validation for OncoSec’s clinical development program,” chief clinical and regulatory officer Sharron Gargosky added. “As we launch our upcoming Phase IIb Pisces clinical trial, we look forward to collaborating closely with the FDA at this important stage of our clinical program.”

The company’s Phase IIb single-arm study plans to evaluate its ImmunoPulse IL-12 in combination with intravenous anti-PD-1 antibody in patients with stage III or IV metastatic melanoma.

The primary endpoint of the study will be overall response rate at 24 weeks, according to OncoSec, with secondary endpoints of best overall response rate, duration of response, median progression-free survival and overall survival. The clinical trial is slated to begin in the 2nd half of this year, the company reported.

ONCS shares were trading at $1.52 in morning activity today, up 9.1%.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Wall Street Beat Tagged With: OncoSec Medical

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS